BioCentury
ARTICLE | Company News

CytImmune, OctoPlus Technologies B.V. deal

May 26, 2003 7:00 AM UTC

The companies partnered to formulate tumor necrosis factor (TNF) to treat solid tumors. The deal combines OctoPlus' formulation technologies with CytImmune's colloid gold drug delivery technology. Oc...